Northwest Biotherapeutics Inc NWBO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NWBO is a good fit for your portfolio.
News
-
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
-
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
-
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
Trading Information
- Previous Close Price
- $0.76
- Day Range
- $0.72–0.88
- 52-Week Range
- $0.40–1.12
- Bid/Ask
- $0.84 / $0.88
- Market Cap
- $986.54 Mil
- Volume/Avg
- 2.4 Mil / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 448.82
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 22
- Website
- https://www.nwbio.com
Valuation
|
Metric
|
NWBO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 448.82 |
Price/Cash Flow | — |
Price/Earnings
NWBO
Financial Strength
|
Metric
|
NWBO
|
|---|---|
Quick Ratio | 0.14 |
Current Ratio | 0.17 |
Interest Coverage | −12.79 |
Quick Ratio
NWBO
Profitability
|
Metric
|
NWBO
|
|---|---|
Return on Assets (Normalized) | −175.05% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NWBO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bztsw | $458.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mbnzk | $90.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dxhryf | $88.8 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Qmlzmp | $40.1 Bil | |
MRNA
| Moderna Inc | Nsnc | $30.4 Bil | |
ARGX
| argenx SE ADR | Lzpj | $27.0 Bil | |
BNTX
| BioNTech SE ADR | Gpmrl | $23.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pgyzl | $21.5 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dklkccy | $17.4 Bil | |
INCY
| Incyte Corp | Hsybmq | $12.1 Bil |